FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

LAURUSLABS

1,009
+75.75 (8.12%)
Updated 03:29 03/08 IST

LAURUSLABS Buy or Sell - FrontPage Forums

0 Users have submitted 0 trade ideas of Rs. 0 for LAURUSLABS
Disclaimer
0% Bullish
0% Bearish

LAURUSLABS Buy or Sell - Brokerage Reports

No. of reports in last year
1
No. of analysts
1
Average Consensus Forecast
471
Consensus Potential
-98.14%
See LAURUSLABS Share Price Targets >>

LAURUSLABS Ratings

Long term LAURUSLABS rating by FrontPage users
5/5 (3 Ratings)
Find answers to all your questions on live LAURUSLABS message board: Is LAURUSLABS buy or sell? Should I buy LAURUSLABS shares? Why are LAURUSLABS shares falling? Should I invest in LAURUSLABS stock?

  1. Home
  2. LAURUSLABS Forum

LAURUSLABS Share Price Discussion

Great Eagle Analysis in LAURUSLABS
#LAURUSLABS MEDIUM TERM BUY MODE TGT 762/1028 ...
Like
Reply
A
Reputation: 2,612 • Today 6:34 AM
ASHISH SHAH in LAURUSLABS
Intraday Short View Laurus Labs looks good 1040...

*LAURUS LABS 1050 TO 984. SAFE PLAYERS BOOK OR KEEP TSL*
💫✨⚡⭐🔥💥💚❤️
Like
Reply
A
Reputation: 2,612 • Today 5:34 AM

Intraday Short View
Laurus Labs looks good 1040-1050
Negated above 1080
Tgt open
Like
Reply
Like
Reply (2)
Latest replies
M
Reputation: 78,304 • Today 2:49 AM

Type
Buy
Instrument
LAURUSLABS
Entry Price
₹973.95
Price@Trade
₹973.95
Target Price
₹1,050
Stop Price
₹940
Valid Till
Aug 3, 2020 3:20 AM
Margin
₹292,185 approx for 300 Qty
Status
Exited
Exit Price
₹987.9
Net P&L
+₹4,185 (+1.43%)
Like
Reply (1)
Latest replies
Mayur @mayurgoyal
Today 3:03 AM

Update
Exited
Exit Price
₹987.9
Net P&L
+₹4,185 (+1.43%)
N
Reputation: 4,625 • Yesterday 3:26 AM
Ashok Leyland may prove to be the dark horse in auto space: Abhimanyu Sofat
Considering the stock is quite diversified, from commercial vehicles to defence, you could see a lot of traction coming over next two-three years.
The Economic Times
Like
Reply
N
Reputation: 4,625 • Aug 1 3:16 AM
Pharma stocks gain as investors rush to buy defensives
In the last five trading sessions, Nifty Pharma index has rallied 9% as against 1% drop in the Nifty.
The Economic Times
Like
Reply
M
Reputation: 78,304 • Jul 31 8:34 AM

Type
Buy
Instrument
LAURUSLABS
Entry Price
₹932.55
Price@Trade
₹932.55
Target Price
₹948
Stop Price
₹925
Valid Till
Jul 31, 2020 3:20 AM
Margin
₹93,255 approx for 100 Qty
Status
Stoploss Hit
Exit Price
₹925
Net P&L
-₹755 (-0.81%)
Like
Reply (1)
Latest replies
TrackerBot @trackerbot
Jul 31 8:46 AM

Update
Stoploss Hit
Exit Price
₹925
Like
Reply
N
Reputation: 4,625 • Jul 30 1:28 AM
Aarti Drugs’ API business gains as pharma firms diversify raw material sourcing from China
Company’s stock among those that gained substantially during COVID-19 days. Drug maker planning contract manufacturing of specialty products. Other Indian pharma companies also benefit as buyers, both domestic and global, scout for non-Chinese suppliers of raw materials.
Moneycontrol
Like
Reply
N
Reputation: 4,625 • Jul 30 11:33 AM
Laurus Labs' net up 11 times to Rs 172 crore in Q1
Revenues from operations were up 77 percent during the quarter under discussion to Rs 974 crore, a press release said.
Moneycontrol
Like
Reply
N
Reputation: 4,625 • Jul 30 10:36 AM
Laurus Labs Q1 results: Net profit up 11 times to Rs 172 crore
Revenues from operations were up 77 per cent during the quarter under discussion to Rs 974 crore, a press release said.
The Economic Times
Like
Reply

FROM SOURCES : LAURUS LAB LIKELY TO REPORT 148 CR PROFIT VS EXPECTATION OF 92 CR TODAY. 5:1 STOCK SPLIT ALSO POSSIBLE.
Like
Reply
Great Eagle Analysis in LAURUSLABS
#LAURUSLABS MEDIUM TERM BUY MODE TGT 762/1028 ...

Laurus lab Hit my first tgt. 21.92% return from my suggested level. Book 70% and hold rest for final target.
Like
Reply
N
Reputation: 4,625 • Jul 29 4:46 AM
FPIs, MFs both turn gung-ho on these 12 stocks; they’re worth a look
Domestic mutual funds and foreign portfolio investors (FPIs) both turned bullish on at least a dozen common stocks in June quarter.
The Economic Times
Like
Reply

Type
Sell
Instrument
LAURUSLABS
Entry Price
₹768.2
Price@Trade
₹767.35
Target Price
₹713.15
Stop Price
₹799.25
Valid Till
Jul 29, 2020 3:20 AM
Margin
₹99,097.8 approx for 129 Qty
Status
Validity Over
Exit Price
₹764
Net P&L
+₹541.8 (+0.55%)
Like
Reply (2)
Latest replies
TrackerBot @trackerbot
Jul 29 4:19 AM

Update
Trade Entered
Entry Price
₹768.2
TrackerBot @trackerbot
Jul 29 8:50 AM

Update
Validity Over
Exit Price
₹764
Net P&L
+₹541.8 (+0.55%)

Type
Sell
Instrument
LAURUSLABS
Entry Price
₹716
Price@Trade
₹716
Target Price
₹690.35
Stop Price
₹729.5
Valid Till
Jul 24, 2020 3:20 AM
Margin
₹99,524 approx for 139 Qty
Status
Stoploss Hit
Exit Price
₹729.5
Net P&L
-₹1,876.5 (-1.89%)
Like
Reply (1)
Latest replies
TrackerBot @trackerbot
Jul 24 5:10 AM

Update
Stoploss Hit
Exit Price
₹729.5

LAURUSLABS - chart - 1064699
#LAURUSLABS at 716
#ichimoku 45 showing a big run up pending
Like
Reply
S
Reputation: -1,873 • Jul 23 7:04 AM

Type
Sell
Instrument
LAURUSLABS
Entry Price
₹702.8
Price@Trade
₹702.8
Target Price
₹690
Stop Price
₹715
Valid Till
Aug 21, 2020 3:20 AM
Margin
₹281,120 approx for 400 Qty
Status
Stoploss Hit
Exit Price
₹715
Net P&L
-₹4,880 (-1.74%)
Like
Reply (1)
Latest replies
TrackerBot @trackerbot
Jul 23 8:25 AM

Update
Stoploss Hit
Exit Price
₹715
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • LAURUSLABS - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization4,254.94
    Enterprise Value5,170.37
    Price to Earnings30.81
    Price to Book Value2.68
    Return on Capital Employed0.13
    Return on Equity0.11
    Face Value10
    Dividend YieldNA
  • LAURUSLABS - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    5-Aug-19HDFC SecuritiesBuy471
    17-Jul-19HDFC SecuritiesBuy515
    1-Jul-19Kotak SecuritiesBuy430
    6-May-19Motilal OswalBuy470
    26-Apr-19HDFC SecuritiesBuy417
    LAURUSLABS Brokerage Price Target
  • LAURUSLABS Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Aug 3955.251075.159551006.65
    Jul 31825945815933.25
    Jul 30770799.9760.65790.25
    Jul 29765.5794757.95763.85
    Jul 28725.9765.5722.55759.95
  • LAURUSLABS Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹689.2
    30 Day Moving Average₹638.51
    50 Day Moving Average₹575.09
    100 Day Moving Average₹494.96
    200 Day Moving Average₹435.85
  • LAURUSLABS - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue2,039.291,891.920.08
    Operating Profit408.75415.62-0.02
    Profit Before Tax240.91247.63-0.03
    Net Income173.14202.57-0.15
  • LAURUSLABS - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds1,5901,513.30.05
    Total Liabilities1,7271,612.410.07
    Total Assets3,3183,125.710.06
  • LAURUSLABS - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity368.6320.060.15
    Cash from Investing Activity-417.48-280.950.49
    Cash from Financing Activity48.99-47.31-2.04
    Net Cash Flow0.12-8.21-1.01
  • LAURUSLABS - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.060.08
    Return on Equity0.110.15
    Return on Capital Employed0.130.16
  • LAURUSLABS - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue0.54
    3 Year CAGR Growth in Operating Profit0.99
    3 Year CAGR Growth in EBIDTA0.83
    3 Year CAGR Growth in Net Income1.36
    3 Yr CAGR Growth - Diluted EPS0.82
  • LAURUSLABS - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue1.82
    5 Year CAGR Growth in Operating Profit1.82
    5 Year CAGR Growth in EBIDTA1.92
    5 Year CAGR Growth in Net Income0.96
    3 Yr CAGR Growth - Diluted EPS0.44
  • LAURUSLABS - Recent News

    keyboard_arrow_down
    NewsBot
    Aug 1 3:16 AM
    Pharma stocks gain as investors rush to buy defensives
    The Economic Times
    NewsBot
    Jul 30 11:33 AM
    Laurus Labs' net up 11 times to Rs 172 crore in Q1
    Moneycontrol
    NewsBot
    Jul 30 10:36 AM
    Laurus Labs Q1 results: Net profit up 11 times to Rs 172 crore
    The Economic Times
    NewsBot
    Jul 29 4:46 AM
    FPIs, MFs both turn gung-ho on these 12 stocks; they’re worth a look
    The Economic Times
    NewsBot
    Jul 17 4:26 AM
    Share market update: 28 stocks hit 52-week highs on NSE - The Economic Times
    The Economic Times
    NewsBot
    Jul 14 4:46 AM
    Share market update: 35 stocks hit 52-week highs on NSE - The Economic Times
    The Economic Times
    NewsBot
    Jul 13 12:38 PM
    Hot Stocks | Some profit-booking likely; Sunteck Realty, Laurus Labs two buy calls for the short-term
    Moneycontrol
    NewsBot
    Jul 2 4:23 AM
    Lovable Lingeri Standalone March 2020 Net Sales at Rs 10.58 crore, down 61.92% Y-o-Y
    Moneycontrol
    NewsBot
    Jun 29 3:38 AM
    Bluewater Investment offloads Rs 632 crore stake in Laurus Labs, Titan Europe sells shares worth Rs 146.74 crore in Wheels India
    Moneycontrol
    NewsBot
    Jun 29 2:36 AM
    NSE-BSE bulk deals: Blue Water Investment sells Laurus Labs
    The Economic Times
  • LAURUSLABS - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Aurobindo Pharma Ltd. NSE: AUROPHARMA...
    Cipla Ltd. NSE: CIPLA | BSE: 500087 |...
    Biocon Ltd. NSE: BIOCON | BSE: 532523...
    Lupin Ltd. NSE: LUPIN | BSE: 500257 |...
    Dr. Reddy's Laboratories Ltd. NSE: DR...
    Glenmark Pharmaceuticals Ltd. NSE: GL...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Divi's Laboratories Ltd. NSE: DIVISLA...
    Apollo Hospitals Enterprise Ltd. NSE:...
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.

PrivacyTerms
FrontPage © 2020